APA (7th ed.) Citation

Kießling, M., Nicolay, J. P., Schlör, T., & Klemke, C. (2017). NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. OncoTarget, 8(28), . https://doi.org/10.18632/oncotarget.17669

Chicago Style (17th ed.) Citation

Kießling, Michael, Jan Peter Nicolay, Tabea Schlör, and Claus-Detlev Klemke. "NRAS Mutations in Cutaneous T Cell Lymphoma (CTCL) Sensitize Tumors Towards Treatment with the Multikinase Inhibitor Sorafenib." OncoTarget 8, no. 28 (2017). https://doi.org/10.18632/oncotarget.17669.

MLA (9th ed.) Citation

Kießling, Michael, et al. "NRAS Mutations in Cutaneous T Cell Lymphoma (CTCL) Sensitize Tumors Towards Treatment with the Multikinase Inhibitor Sorafenib." OncoTarget, vol. 8, no. 28, 2017, https://doi.org/10.18632/oncotarget.17669.

Warning: These citations may not always be 100% accurate.